Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
AKT1 act mut
|
lymphoma
|
decreased response |
|
Doxorubicin
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).
|
18708578
|
AKT1 act mut
|
lymphoma
|
predicted - sensitive |
|
Doxorubicin + Sirolimus
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).
|
18708578
|
AKT1 act mut
|
Advanced Solid Tumor
|
no benefit |
Akt Inhibitor (Pan)
|
Triciribine
|
Phase I |
Actionable |
In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).
|
20644979
|
AKT1 act mut
|
lymphoma
|
no benefit |
|
Sirolimus
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).
|
18708578
|